Combinostics

Combinostics operates at the intersection of enterprise healthcare software, neuroimaging analytics, and clinical decision support. Its product set spans automated brain MRI quantification through cNeuro® cMRI, integrated imaging and patient-data analysis through cNeuro® cDSI, and disease-specific reporting for dementia, multiple sclerosis, traumatic brain injury, and epilepsy. That combination differentiates it from imaging tools focused only on segmentation or measurement: Combinostics presents quantitative biomarkers alongside diagnostic support and progression assessment. The company’s 2026 collaboration with 3DR Labs points toward workflow integration in neuroradiology rather than a standalone algorithm sold in isolation. Its acquisition by SyntheticMR also gives the technology a strategic position within a broader neuroimaging portfolio, potentially improving access to imaging providers and complementary MRI capabilities. The company appears to be a specialized, clinically oriented participant in AI-assisted brain imaging, with differentiation grounded in multimodal patient-data integration, automated quantification, and disease-focused reporting rather than broad general-purpose healthcare AI.

Combinostics was founded in 2014 and built its financing history through three recorded seed rounds, a non-equity assistance round, and a 2019 Series A. The Series A raised approximately $4.32 million, led by Industrifonden and NordicNinja VC, while cumulative funding is listed at approximately $4.75 million. The funding pattern suggests an early-stage product development period followed by institutional backing to commercialize its neurodiagnostics platform. A major inflection point arrived on Nov 28, 2024, when SyntheticMR agreed to acquire the company for approximately $4.54 million; completion was announced on Jan 2, 2025. Since then, the trajectory has been defined less by standalone fundraising and more by integration into SyntheticMR’s operating and product ecosystem. The 2026 3DR Labs collaboration provides evidence of continued external commercialization in neuroradiology workflows, while regulatory and corporate reporting during January, February, and August 2026 indicates ongoing portfolio activity. Combinostics reports an employee band of 11–50, but there is no quantified hiring trend, revenue series, customer count, or product-launch history. Growth therefore appears to be strategically acquisition-led, with clinical distribution and platform integration now more important than additional venture financing.